ADC TOXICITY ATLAS
Atlas
Payloads and Linkers
Payloads
Targets
Methods
← Payloads & linkers
Payload · Maytansinoid
DM4 (free)
Tubulin inhibitor
C[C@@H]1[C@@H]2C[C@]([C@@H](/C=C/C=C(/CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@@H]([C@]4([C@H]1O4)C)OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)S)C)\C)OC)(NC(=O)O2)O
Physicochemistry
Properties
MW
780.4
Da
XLogP3
3.2
logD₇.₄
3
TPSA
157
Ų
pKa
10.3
Charge pH 7.4
0
H-bond donors
3
H-bond acceptors
11
Bystander
Yes
PubChem CID
11686439
Bioactivity
ADCdb-reported ADC potency (IC50): KB cells 0.15 +/- 0.08 nM; JEG-3 0.20 +/- 0.10 nM; IGROV-1 1.00 +/- 0.40 nM; END-2 0.20 ug/mL; END-1 74.6 ug/mL. Source: ADCdb DRG0GKOZH.
11 agents
ADCs built on this payload
Any-grade
Grade 3+
Agent · target
Ocular
Hepatic
Neutrop.
Thrombo.
Anemia
GI
ILD
Neuro.
Mirvetuximab soravtansine
FOLR1
59
57
22
17
18
29
10
36
JBH-492
CCR7
56.3
50
4
8
43
4
Cantuzumab ravtansine
MUC1
50
Praluzatamab ravtansine
ALCAM
49
22.2
2
4
9.1
46.5
16.2
Tusamitamab ravtansine
CEACAM5
38
1.1
1.1
3.3
22.8
13
Anetumab ravtansine
MSLN
37
29
21
16
58
37
SAR-566658
MUC1 (CA6 epitope carried on MUC1)
36
Coltuximab ravtansine
CD19
25
79
84
57
87
23
8
LY3076226 (IMC-D11)
FGFR3
12
28
0
20
12
44
0
16
Indatuximab ravtansine
SDC1
6.3
MEN-1309 (OBT076)
LY75
5.9
41
41
0%
severity
100%
0
Assessed · clear
true 0%
No data
never assessed